anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators are undertaking a parallel group, multicentre, randomised controlled trial of 240 refractory ITP adult patients from 14 medical centers in China. One part of the participants are randomly selected to receive recombinant human thrombopoietin (given subcutaneously at a dose of 300 Units/kg for 14 consecutive days,following with a flexible dosage depending on platelet count until the 29th day), combining with rituximab (given intravenously at a dose of 100 mg weekly for 4 weeks, i.e. Day 1, 8, 15, 22; the others are selected to receive low-dose of rituximab treatment (given intravenously at a dose of 100 mg weekly, i.e. Day 1, 8, 15, 22). Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study. In order to report the efficacy and safety of the combination therapy compared to conventional rituximab therapy for the treatment of adults with refractory ITP.
PROBLEM TO BE SOLVED: To obtain an eye lotion composition manifesting excellent antiseptic activities even if an addition amount of an antiseptic agent is small, capable of being stably formulated with a high molecular polysaccharide having a negative charge by especially formulating two kinds of the medicines with a cationic surfactant as the antiseptic agent. SOLUTION: This eye lotion composition includes (A) a cationic surfactant as an antiseptic agent, (B) a buffer, (C) a chelating agent, (D) a high molecular polysaccharide. The component A is preferably benzalkonium chloride, benzethonium chloride, etc. The concentration thereof is 0.0001-0.001wt.%. The component B is preferably tromethamine, boric acid, etc. The component C is preferably ethylenediamine tetraacetate disodium salt, etc. The component D is preferably hyaluronic acid, chondroitinsulfuric acid, etc.
Circumferential ablation with radiofrequency ablation will be performed for each segment of the BE starting from the proximal end with one ablation at 12J/cm2, followed by cleaning of mucosal slough with esophageal cap, patient extubation, cleaning of ablation device with wet gauze, and finally a second ablation at 12 J/cm2 (1 × 12J/cm2-clean-1 × 12 J/cm2). Focal ablations will be performed with three consecutive ablations at 12 J/cm2 without cleaning (simplified protocol).
Background: Behavioral treatments are recommended as first-line interventions for tic disorders (TDs) in children and adults, which affect 2.99% of children. However, the effectiveness of these interventions is often undermined by the limited compliance especially of young individuals with the demanding treatment protocols. Addressing this issue, gamification of the treatment can enhance engagement and adherence in children. In the context of TDs, gamification provides significant additional benefits, particularly robust immediate feedback. This feedback can counteract the negative reinforcement processes, wherein the tic, believed to relieve the unpleasant premonitory urge, becomes consolidated. The investigators developed a gamified Protocol XTics, which leverages the previously untapped potential of combining various tic triggers with immediate reinforcement of tic suppression. The investigators evaluated the clinical value of XTics, focusing particularly on the benefits of immediate reward contingency in enhancing tic suppression performance.

Methods: The investigators developed a game incorporating tic triggers validated in a prior study. In one version of the game, its progression was influenced by real-time input from an experimenter who continuously monitored the participant's tics, rewarding tic suppression with favorable game outcomes. Employing a crossover design, the investigators trained 35 participants, aged 7-15, in both this version and another where the game's progression was independent of tic suppression. Following two online group Exposure and Response Prevention (ERP) training sessions, each participant engaged in three hourly sessions for each of the two conditions. Our evaluation focused on how the overall XTics protocol influenced tics and how this influence differed between the contingent and non-contingent versions of the game.
We consider the disorders of arousal and sleep-related hypermotor epilepsy as genetic twin-conditions, one without, one with epilepsy. They share an augmented arousal-activity during NREM sleep with sleep-wake dissociations, culminating in sleep terrors and sleep-related hypermotor seizures with similar symptoms. The known mutations underlying the two spectra are different, but there are multifold population-genetic-, family- and even individual (the two conditions occurring in the same person) overlaps supporting common genetic roots. In the episodes of disorders of arousal, the anterior cingulate, anterior insular and pre-frontal cortices (shown to be involved in fear- and emotion processing) are activated within a sleeping brain. These regions overlap with the seizure-onset zones of successfully operated sleep-related hypermotor seizures, and notably, belong to the salience network being consistent with its hubs. The arousal-relatedness and the similar fearful disorientation occurring in sleep terrors and hypermotor seizures, make them alike the acute stress-responses emerging from sleep; triggered by false alarms. An acute stress-response can easily mobilize the hypothalamo-pituitary-adrenal axis (preparing fight-flight responses in wakefulness); through its direct pathways to and from the salience network. This hypothesis has never been studied.
The purpose of this investigation was to investigate whether there was an association between the Naples prognostic score and the development of acute kidney injury (AKI) in ST-elevation myocardial infarction (STEMI) patients following primary percutaneous coronary intervention (pPCI). The study comprised 2901 consecutive STEMI patients who had pPCI. For each patient, the Naples prognostic score was determined. To evaluate the predictive performance of the Naples score (which included either continuous and categorical variables), we developed a Nested model and a nested model combined with the Naples score. The Naples prognostic score was the most significant predictor of AKI occurrence after admission creatinine, age, and contrast volume. The continuous Naples prognostic score model provided the best prediction performance and discriminative ability. The C-index of the Nested and full models with continuous Naples prognostic score were significantly higher than that of the Nested model. The decision curve analysis found that the overall model had a higher full range of probability of clinical net benefit than the baseline model, with a 10% AKI likelihood. The present study found that the Naples prognostic score may be useful to predict the risk of AKI in STEMI patients undergoing pPCI.
The present invention relates to a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), said cell being further modified to render its MALT1 protease activity constitutive active. The present invention further relates a said cell of the human immune system for use as a medicament. In particular, the present invention relates to said cell for use in adoptive T cell therapy. The invention also comprises a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), and further modified to render its MALT1 protease activity constitutive active for use in a method of treating cancer. The invention also relates to a method for generating a cell of the human immune system, comprising modifying a cell to render MALT1 protease activity constitutive active. The invention further relates to an in vitro method of enhancing the activity of a cell of the human immune system transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR), comprising modifying said cell in that MALT1 is rendered constitutive active. The invention also comprises an in vitro use of constitutive active MALT1 for enhancing the activity of a cell transduced or transfected with a T cell receptor (TCR) or chimeric antigen receptor (CAR).
The invention discloses a manufacturing technique for preparing frozen-out gene engineering bacteria competent cells. The invention also relates to a prescription of protecting agent, which is wide in application by taking as the host bacteria for transferring outer DNA in researching, developing, producing and checking of biotechnology. The protecting agent is one of the most fundamental matching consumption preparations. The invention utilizes vacuum freeze drying technology to deal with the poor gene engineering bacteria competent cells, and can save the cells steadily at a wide temperature range of 20 DEG C below zero to 4 DEG C for long time while keeping high transformation efficiency. The invention enables the cells to store and long-distance transport conveniently. The invention relates to a manufacturing technique for preparing frozen-out competent cells, quality inspection regulation and the frozen-out protecting agent, comprising culture conditions of gene engineering bacteria, technological processes of freezing and drying and the composition and matching of the protecting agent. The protecting agent is formed by water and one or arbitrary combination of the following materials: gelatin, degreasing milk, dextran, trehalose, sucrose, sorbitol or mannitol.
PURPOSE:The title therapeutic agent that contains naturally occurring phytoncides as an active ingredient. CONSTITUTION:An extract of naturally occurring phytoncides is combined with distilled water and an organic solvent, then the lipophilic organic solvent phase is separated, subjected to chromatography to collect the antitrichophyton fractions. The fractions are concentrated to give the objective therapeutic agent for Trichophyton of high purity. The agent may be directly applied to human bodies in the form of a powder, or mixed with a solid carrier (such as diluent or excipient) or adsorbed on the carrier and applied. The content of the naturally occurring phytoncides is 0.5-20wt% of triptance based on the whole preparation. The agent may additionally contain a keratolytic agent such as salicylic acid, other antibacterials and antibiotics. The application of the agent to the affected parts is carried out once to several times until itching and inflammation are removed or relieved.
OBJECTIVE: Aim: The aim of the study was to determine the relationship of residual renal function, markers of inflammation and protein-energy expenditure with annual survival in patients undergoing hemodialysis.
PATIENTS AND METHODS: Materials and Methods: The work was a prospective cohort study and included 299 patient data. Residual kidney function was determined by urine volume of more than 250 ml per day to assess the effect. According to this criterion, the patients were divided into two groups. The degree of chronic inflammation was assessed by the content of acute phase proteins (ferritin and C-reactive protein) in the blood serum. The serum albumin level was chosen as a marker of protein-energy expenditure. The survival rate of patients with residual renal function was higher as compared to patients without it (p<0.001).
RESULTS: Results: In the current study, the absence of residual kidney function increased the risk of mortality from all causes in patients who had recently undergone hemodialysis by almost 30 times during the first year of substitution therapy. C-reactive protein was also associated with poorer survival in these patients (HR=1.01; 95% CI: 1-1.02), while albumin was inversely associated with mortality (HR=0.92; 95% CI: 0.87-0.98).
CONCLUSION: Conclusions: Thus, residual renal function and higher serum albumin levels by the time maintenance hemodialysis begins are independent predictors of the best survival during the first year of replacement therapy. The presence of residual kidney function of less than 250 ml and a higher level of C-reactive protein correlated with an increased risk of mortality in these patients.
The invention relates to a process for the immobilization of compounds comprising nucleophilic groups. According to the process of the invention a polymer comprising an amido group is swollen in a buffer. For this purpose any buffer is suitable which contains no amino, sulfhydryl and/or hydroxy groups in the molecule. To the swollen polymer a solution of a quinone - preferably p-benzoquinone - in a water miscible organic solvent is added and the mixture is activated at 273 DEG -343 DEG  K. for 0.5-48 hours - preferably for 24 hours. The unreacted quinone is washed out with an aqueous solution of a water miscible organic solvent and thereafter water and/or a buffer. To the purified gel at a pH value between 3 and 11 - preferably between 6 and 8 - a buffered solution of a compound comprising a nucleophilic group is added, the suspension is incubated at 260 DEG -313 DEG  K. for 24 hours, the gel is separated and the non-bound compound comprising a nucleophilic group is removed by washing.
INTRODUCTION: Susceptibility to secondary infection often increases after primary infection. Secondary infections can lead to more severe inflammatory injuries; however, the underlying mechanisms are not yet fully elucidated.
OBJECTIVE: To investigate whether esketamine treatment immediately after primary lipopolysaccharide (LPS) exposure could alleviate cognitive impairment caused by secondary infection.
METHODS: Mice were injected intraperitoneally (IP) with LPS (5 mg/kg) 10 days apart. Esketamine (10, 15, or 30 mg/kg) was administered IP immediately after the primary LPS injection. Splenectomy or subdiaphragmatic vagotomy (SDV) was performed 7 days before secondary LPS exposure or broad-spectrum antibiotic administration.
RESULTS: Splenomegaly was observed after the primary LPS injection on Days 3 and 10. Splenomegaly was attenuated by treatment with 30 mg/kg esketamine. Esketamine treatment prevented increased plasma proinflammatory cytokines levels and cognitive dysfunction induced by secondary LPS exposure. Mice that underwent splenectomy or SDV had lower proinflammatory cytokines levels, higher hippocampal brain-derived neurotrophic factor (BDNF) levels, and improved cognitive function 1 day after secondary infection, which was not further improved by esketamine. Fecal microbiota transplantation (FMT) from endotoxic mice treated with esketamine attenuated hippocampal BDNF downregulation and cognitive dysfunction only in pseudo germ-free (PGF) mice without splenectomy. FMT with fecal suspensions from esketamine-treated endotoxic mice abrogated splenomegaly only in PGF mice without SDV. Blocking BDNF signaling blocked esketamine's ameliorating effects on secondary LPS exposure-induced cognitive dysfunction.
CONCLUSION: The intestinal flora/subdiaphragmatic vagus nerve/spleen axis-mediated hippocampal BDNF downregulation significantly affected secondary LPS-induced systemic inflammation and cognitive dysfunction. Esketamine preserves cognitive function via this mechanism.
IOL with misoprostol oral tablets (Angusta®) 25 ug every second hour, up to eight doses, or until painful contractions are obtained. Thereafter IOL will proceed according to clinical practice.
This is a pilot study following a single case experimental design with multiple baselines across subjects (MBD).

People included in the protocol will benefit from 2 hours of daily treatment during 6 to 7.5 weeks. The first 2 weeks will be dedicated to baseline measurement of their upper limb (UL) status with daily treatment for balance and gait control without any treatment of the upper limb. The rest of the time will be dedicated to upper limb treatment exclusively. It will be divided into 2 UL training periods, one of them including a 30mn treatment with the luna EMG robot. The duration of second period will be randomly defined between 2 to 3.5 weeks and the last period will last 2 weeks. The treatment during the first UL treatment period will be randomly allocated to Luna EMG treatment or not. The next period will thus follow the inverse scheme (without if the first contains Luna EMG treatment). The fluidity will be assessed through pointing movements assessed every two days. Evaluation of motor deficiency (Fugl Meyer) and functional status (ARAT score) of the UL will be weekly assessed after the inclusion visit. 3D motion analysis of the UL will also be weekly performed.

All patients will benefit from a regular follow-up and from an organized care protocol. The sessions will be intensive, all subjects will be able to benefit from the new treatment (LUNA EMG). We can expect a direct individual benefit from the proposed intensive treatment, at least for precision of UL movements.
A system and method is provided for sorting a plurality of data records. The method includes the steps of collecting a plurality of data entries from a data record of the plurality of data records. The method further assigns each data entry of the plurality of data entries with a unique entry ID. An initial state of a given data entry of the plurality of data entries is also identified, and a given state is assigned to the given data entry. A change in state of the given data entry is determined from the initial state to the given state. The given data entry is sorted according to a first criteria and a second criteria, with the sorting comprising assigning a score to the given data entry. The given data entry is prioritized based on the score assigned to the given data entry respective of a score assigned to each remaining data entry of the plurality of data entries. An output representing a prioritized list of the plurality of data entries is generated based on a respective score that can be displayed in a display.
The device is currently in use in an ongoing IRB approved protocol Pro00050297 "Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy". Brachytherapy is an integral part of the management of many gynecological cancers, which uses radioactive isotopes to deliver radiation treatment in close proximity to the target. The protocol uses the device in the setting of gynecologic brachytherapy to monitor real time doses, with a primary endpoint of feasibility and accuracy. Accrual is ongoing, however, the device has initially given consistent results, within 3% of the expected values. This initial experience is intentionally designed with the simplest geometry and positioning. This protocol has a similar design to the initial brachytherapy trial, but with the significant difference that the monitoring will be performed during external beam radiotherapy. Calibration procedures are different in this scenario, and the considerations of when and where dose monitoring will be useful are distinct from these considerations in brachytherapy.
INTRODUCTION: Studies addressing the prevalence of cardiac amyloidosis (CA) among patients with spinal stenosis (SS) are lacking. The identification of the red flags (RF) of CA could lead to early detection of cases of CA. The primary objective of this study was to address the prevalence of RF of CA among patients with SS.
METHODS: Transversal study including consecutive cases with SS and yellow ligament hypertrophy (YLH). A clinical assessment that included electrocardiogram, echocardiogram and urine and blood test was performed. A clinical suspicion of CA was defined by the presence of left ventricular hypertrophy plus any RF.
RESULTS: One hundred and three patients with SS and YLH were assessed. The prevalence of RF was high: heart failure: 18.4%; aortic stenosis: 1.9%; carpal tunnel syndrome: 7.8%; bicipital tendon rupture: 1.9%; arterial hypotension: 17.4%; polyneuropathy symptoms: 51.5%; pseudoinfarction pattern: 3.9%; low voltages: 15.5%; conduction abnormalities: 15.5%; decreased longitudinal strain: 25.3%; apical sparing pattern: 3.9%. The 57.3% of the cohort met the CA suspicion criteria.
CONCLUSION: The prevalence of RF of CA is high among patients with SS and YLH. A high proportion of patients met the CA suspicion criteria.
Patients receive low-dose vorinostat PO QD on days 1-3 and high-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive vorinostat and carboplatin as in Arm I.
Most patients with autoimmune diseases depend on hormones for life, and when poorly controlled, they are at risk of disability or even death. Studies have found that the abnormal T cell function of patients is closely related to the occurrence and development of the disease. Therefore, reducing the T cells in the patient's body or blocking the function has become the latest breakthrough in treatment. CD7 is a specific antigen on the surface of T cells. CD7 CAR-T can specifically attack T cells and has the potential to cure. In 2019, "Science Translational Medicine" magazine reported that the Marko Radic team demonstrated that CAR-T cells can achieve significant and long-lasting effects in the treatment of systemic lupus erythematosus (SLE) through animal experiments. In 2021, "NEJM" magazine reported the clinical efficacy of CAR-T cells in the treatment of SLE. In the same year, "Journal of Clinical Oncology" reported the clinical efficacy and safety of CD7 CAR-T cells in the treatment of T cell ALL.

Based on the current research status, we applied to clinical research on the treatment of refractory autoimmune diseases by targeting CD7 CAR-T cells. The selection criteria is patients with refractory autoimmune diseases. The purpose is to evaluate the safety and effectiveness of targeted CD7 CAR-T cell therapy through this clinical trial study, and to provide clinical evidence and experience reference for the application of CAR-T cell technology in the treatment of refractory autoimmune diseases.
Keloids are pathologic responses to cutaneous injury. Current treatments, such as topical and intralesional steroids and even surgical excision, have limited efficacy, creating a demand for improved therapies. Our study explores the functioning of dupilumab, an interleukin-4 and inter-leukin-13 signaling pathway inhibitor, in this context. We have reviewed the literature for using dupilumab to treat keloids, evaluating safety and efficacy and offering recommendations for its application. We searched PubMed and Google Scholar using "Dupilumab" and "Keloid" as keywords. To ensure relevance, we limited the search to English language publications of 2018-2023. Dupilumab exhibited efficacy in keloid treatment, with notable improvements in patients. One patient reported a 50% reduction in the fibrotic plaque and complete resolution of smaller keloids without adverse effects. Two other patients reported successful stabilization and reduction in keloids following dupilumab therapy; however, the 12-week treatment demonstrated no response or reduction in post-treatment size or height of keloidals, with disease progression observed in one patient. One report discouraged the use of dupilumab for keloids due to limited positive responses. Considering dupilumab as the last therapeutic option to treat keloids may benef patients resistant to standard therapies and/or those highly motivated to reduce keloids.